AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03426709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low intensity Internet-delivered psychotherapy
Description: The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the program is 8 weeks. Low Intensity Internet-delivered psychotherapy: Psychoeducation, Healthy living habits, Behavioral activation, Positive Psychology, Mindfulness and Compassion
Study NCT02344706 — intervention group
Intervention type: DEVICE
Intervention: Registration of EEG
Description: EEG is registered for study purposes. No interventions to patient care is done at this stage. Acquisition is done without harming the patient.
Study NCT04653987 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous biliary drainage
Study NCT02782273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
Study NCT02782273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
Study NCT04153994 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Blockade
Description: The ESPB is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
Study NCT03386344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study NCT00318890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: Amifostine will be administered as a subcutaneous injection on a daily basis during radiotherapy.
Study NCT00596791 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tafluprost
Description: prostaglandine analoque
Study NCT04136314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision-Framed Survey
Description: Survey will ask all subjects for will be asked to indicate basic demographic information, such as age, sex, race, and education level. Also, subjects will indicate whether they have been diagnosed with psoriatic arthritis. Importantly, patients will complete the survey questions anonymously, and no direct patient identifiers or HIPPA-protected information will be collected. Subjects will then be asked to indicate their preference for a hypothetical injectable medication after exposure to \[A\] a gain-framed message or \[B\] a loss-framed message.
Study NCT04292730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection
Study NCT03386344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study NCT03386344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study NCT01016275 — intervention group
Intervention type: DEVICE
Intervention: Misago (stent placement)
Description: Misago iliac stent
Study NCT01952002 — intervention group
Intervention type: OTHER
Intervention: Inspiratory Muscle Training
Description: Each session The session itself consisted of the following: two sets of 15 breathe cycles without removing the breathing promoter from the mouth and with the aid of a nose clip and 1-minute interval between sets. For training, we used the breathing promoters Power Breathe® Plus Light and Medium Resistance, possessing 10 levels of load gradation ranging from 17 to 186 cm H2O, which were adjusted for each patient and allowed for the individualized prescription of IMT
Study NCT03249961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TDCS
Description: Placebo stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
Study NCT03249961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal TDCS
Description: Excitatory stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
Study NCT03249961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants will receive Transcranial Magnetic Stimulation (TMS) to allow research investigators to determine the location of the left motor cortex.
Study NCT01940913 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic capsules
Study NCT00814762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV Vaccine 732462
Description: Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.
Study NCT00814762 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine
Description: Two doses of placebo, injected intramuscularly, at an interval of approximately one month
Study NCT04254926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Revie ⊕
Description: Revie ⊕ is a positive approach centered on the resources and strengths of the patient, and it consists of an intervention that focuses on the individual's life review. Revie ⊕ allows specialist nurses to discuss life events with cancer patients, to identify the significant elements, and to explore how the diagnosis has changed their values and preferences. The intervention is geared toward working with the patient to discover their potential, to identify their strategies for coping with the events of their life, and to thereby accompany them in achieving a better understanding of themselves and what defines their identity. The intervention also allows their concerns surrounding death to be addressed, in addition to providing clarity in regard to the life projects. In the end, as a conclusion to the intervention, the patient is provided a booklet recounting the salient features of their life review along with photographs, quotes, or images.
Study NCT03444129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy eating workshop and interactive health game
Description: The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop and interactive health game. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
Study NCT03444129 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy eating workshop
Description: The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
Study NCT01940913 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study NCT02443532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured group education
Description: The group intervention consists of interactive sessions for groups of 5-7 patients, dealing with different aspects of management of type 1 diabetes: insulin therapy and hypoglycemia, management of insulin doses, diet, physical exercise, sick days, etc. The intervention is designed for the acquisition of specific skills of self-management. This intervention is provided by a team including physicians, dietitians, and nurses.
Study NCT02696213 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Systematic, Comprehensive, One to One Training (SCOOT)
Description: An occupational therapist trained by the principal investigator will perform 1.5 hour SCOOT sessions with participants one to two times a week over a period of 6 weeks. SCOOT will provide instruction and practice for performing scooter skills (i.e., instruction on driving, basic and advanced scooter skills) that are embedded in self-selected activities that participants want to perform using their scooters.
Study NCT02696213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic, Comprehensive, One to One Training (SCOOT)
Description: An occupational therapist trained by the principal investigator will perform 1.5 hour SCOOT sessions with participants one to two times a week over a period of 6 weeks. SCOOT will provide instruction and practice for performing scooter skills (i.e., instruction on driving, basic and advanced scooter skills) that are embedded in self-selected activities that participants want to perform using their scooters.
Study NCT02696213 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Six Week Delay
Description: Participants will begin the SCOOT intervention after a six week delay.
Study NCT03177928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transthorathic echocardiogram
Description: In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.
Study NCT01332383 — intervention group
Intervention type: DRUG
Intervention: Naratriptan
Study NCT02843841 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood and fecal sample.
Description: Blood (28 ml) and fecal sample at day 0, 4 days, 3 months and one year after transplantation
Study NCT01668225 — intervention group
Intervention type: PROCEDURE
Intervention: Blood test
Description: Taking blood sample of the patient during the day 3, triggering day, oocyte collection day and pregnancy test day.~Taking the follicular fluid during the oocyte collection day
Study NCT01150097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (reduced tacrolimus)
Description: After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
Study NCT01150097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (reduced tacrolimus)
Description: Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
Study NCT01150097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (tacrolimus elimination)
Description: After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
Study NCT01150097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (tacrolimus elimination)
Description: Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
Study NCT01150097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (tacrolimus control)
Description: Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
Study NCT01150097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.
Study NCT01150097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.
Study NCT03906539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10 mg per day
Study NCT03906539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10 mg per day
Study NCT03906539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Virgin Coconut Oil (VCO)
Description: Capsule VCO (1000 mg/day)
Study NCT03906539 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule - 1 capsule per day
Study NCT03009799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iota-Carrageenan
Description: One drop in each eye 8 times per day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until Day 21
Study NCT03009799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carmellose
Description: 1 drop in each eye 8 times/day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until day 21
Study NCT02557737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
Study NCT02557737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
Study NCT02649556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THS 2.2
Description: Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks.
Study NCT02649556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: Ad libitum use of CC in an ambulatory setting for 26 weeks.~The subject's own preferred brands of CC (no brand restriction) continue to be used as the reference product.
Study NCT02285387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhythm control
Description: 1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~2. Cardioversion after 1 month~3. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~4. If AF recur, RFCA
Study NCT02285387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rate control
Description: 1. No AAD, just anticoagulation~2. HR control between 60\~110bpm (with beta blocker, calcium channel blocker, digoxin)~3. Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study.
Study NCT04618744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 (Insulin) capsule 8 mg BD
Description: 8 mg ORMD-0801, 1 capsule, twice a day, once in the morning and once in the evening.
Study NCT04618744 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT02709330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lunasin Regimen
Description: LunaRich X Capsules, Reliv Now, ProVantage
Study NCT02709330 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Historical control
Description: Matched historical controls will be identified from the PatientsLikeMe database.
Study NCT04241484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezowave 2
Description: Piezowave Myofascial Acoustic Compression Therapy (MyACT), which provides mechanical stimuli delivery to improve circulation and provide relief of pain. The focused sound waves produced by the Piezowave MyACT device are classified by a pressure surge, which is followed by a drop in pressure and a brief negative pressure phase low energy/low pressure application. It is this transformation of mechanical stimuli into biochemical signals, or mechanotransduction, which yields the treatment of myofascial and musculoskeletal pain
Study NCT04526626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation for treatment of lower limb varicose veins (ClosureFast, Medtronic)
Description: Thermal injury to long saphenous vein
Study NCT04051853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be gradually escalated up to 400 mg BID.
Study NCT04051853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Midazolam clearance test
Description: Before start of treatment patients receive a single oral dose of midazolam to phenotype CYP3A4 activity. Blood samples will be taken at several time points to measure sorafenib and midazolam concentrations.
Study NCT04051853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CYP cocktail clearance test
Description: In a subgroup of 15 patients (in the Academic Medical Center Amsterdam), this test will be replaced by an oral cocktail of subclinical doses of caffeine, midazolam, omeprazole, warfarin and metoprolol and will be repeated after 4 weeks of treatment to assess the influence of sorafenib on cytochrome P450 (CYP) 1A2, 3A4, 2C19, 2C9 and 2D6 activity, respectively.
Study NCT02566317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sit-Stand workstation
Description: Installation of a sit-stand desk at work
Study NCT02566317 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Move
Description: A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace
Study NCT02566317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move
Description: A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace
Study NCT02842164 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tension group
Study NCT02842164 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No tension group
Study NCT02842164 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Foley catheter Balloon
Study NCT04017091 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Virtual Reality Cognitive Training
Description: Bimodal VR-Stroop (ClinicaVR: Apartment Stroop) Patient find themselves seated with a virtual apartment, where they see a living room, in front of a flat-screen TV set, a kitchen and a window. This intervention consisted of two Stroop conditions across all 8 sessions. In Condition 1 (Inhibition), Patients indicated when the color named (audio stimulus) matched the color shown (visual stimulus). Participants were to withhold their response in mismatched trials. In Condition 2 (Interference), Participants clicked the mouse when the color heard was the same as the ink color; not the word printed.
Study NCT03634163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neighbourhood exchange
Description: Facilitated coaching support to identify needs and priorities and link with resources - personal, community, friend and family, or from professional service providers; plan and implement a personalized care pathway through community exchange
Study NCT03634163 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life Assessment
Description: Completion of baseline measures
Study NCT03634163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Completion of baseline measures
Study NCT04292730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection
Study NCT00969553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: Dose level 1
Study NCT01393743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Study NCT01393743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Study NCT02529384 — intervention group
Intervention type: OTHER
Intervention: Breast magnetic resonance scanning
Description: Just a muti-b value series in breast MRI
Study NCT03400033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat tablets
Description: Round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
Study NCT03400033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo tablets
Description: Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
Study NCT03400033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa vials
Description: Single-dose, preservative-free vials in unit dose strengths of 2000, 3000, 4000 and 10,000 Units/milliliter administered by the IV route.